Incretin Concepts

Incretin Concepts

Central nervous system effects of glucagon-like peptide 1 At a symposium on nonislet effects of glucagon-like peptide 1 (GLP-1) at the American Diabetes Association (ADA) Scientific Sessions, Remy Burcelin (Toulouse, France) reviewed the controversy as to the extent of GLP-1 action mediated in the central nervous system versus peripheral effects, advancing the concept that a central effect of G...

Incretin-based therapies

Incretin-based therapies have established a foothold in the diabetes armamentarium through the introduction of oral dipeptidyl peptidase-4 inhibitors and the injectable class, the glucagon-like peptide-1 receptor agonists. In 2009, the American Diabetes Association and European Association for the Study of Diabetes authored a revised consensus algorithm for the initiation and adjustment of ther...

Incretin-Based Therapies

INTRODUCTION (BY M.A.N.) — Incretin mimetics and inhibitors of the protease dipeptidyl peptidase (DPP)-4 are new classes of antidiabetic agents first introduced in the years 2005 (exenatide) and 2007 (sitagliptin), respectively. Both use the antidiabetic properties of the incretin hormone, glucagon-like peptide (GLP)-1 (1). This gut-derived peptide hormone not only augments glucose-induced insu...

Gila Monster Lizard & Incretin-mimetics.

Endo-neuro-endocrine incretin pathways.

IN RESPONSE TO NUTRIENT INTAKE, glucagon-like peptide-1 (GLP-1) is secreted from endocrine cells in gastrointestinal mucosa primarily in the distal ileum and colon (3). Numerous actions of GLP-1 have been described, including reduction of blood glucose via several complementary mechanisms and inhibition of gastric emptying. Several recent reviews discuss these actions in some detail (3–7, 10). ...